As per DelveInsight, the Chemotherapy-Induced Diarrhea Market size was found to be USD 80 million in 2022 in the 7MM, which is expected to rise with a significant CAGR during the study period (2019–2032). Chemotherapy-Induced Diarrhea Market dynamics are anticipated to evolve immensely, owing to the rise in the number of prevalent cases of Chemotherapy-Induced Diarrhea and the launch of emerging pipeline therapies. Some of the leading pharma and biotech giants, such as Napo Pharmaceuticals, OnQuality Pharmaceuticals, and others are actively working in the Chemotherapy-Induced Diarrhea therapeutic market.
DelveInsight’s “Chemotherapy-Induced Diarrhea (CID) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chemotherapy-Induced Diarrhea market size, share, trends, and growth opportunities in the seven major markets (7MM) [i.e., the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
The Chemotherapy-Induced Diarrhea market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chemotherapy-Induced Diarrhea: An Overview
Chemotherapy-Induced Diarrhea (CID), also referred to as chemotherapy-related diarrhea (CRD), is a common side effect of cancer treatment. While cytotoxic agents are the main cause of CID, targeted drugs, immunotherapy, and radiotherapy can also cause diarrhea. CID presents a constant challenge in the efficient and tolerable treatment of cancer and is amongst the primary contributors to dose reductions, delays, and cessation of treatment. Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies include radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease, and infections.
The underlying mechanisms of Chemotherapy-Induced Diarrhea remain unclear but are believed to result from a combination of intersecting mechanisms, including inflammation, secretory dysfunctions, GI dysmotility, and alterations in GI innervation. Gastrointestinal (GI) side effects of chemotherapy are a debilitating and often overlooked clinical hurdle in cancer management.
Chemotherapy-Induced Diarrhea Market Key Facts
- The total Chemotherapy-Induced Diarrhea market size in the United States was USD 40 million in 2022.
- In EU4 and the UK, the total Chemotherapy-Induced Diarrhea market size was found to be USD 25 million in 2022.
- In Japan, the total Chemotherapy-Induced Diarrhea market size was found to be USD 15 million in 2022.
- In 2022, the total incident cases of Chemotherapy-Induced Diarrhea were around 1,000,000 in the 7MM, which is expected to rise by 2032 at a significant CAGR.
- In the 7MM, the highest number of total incident cases of Chemotherapy-Induced Diarrhea was observed in the US, with a significant market share in the total cases.
Learn How Chemotherapy-Induced Diarrhea Market Dynamics are Changing with Ongoing Therapeutic Developments in the Domain @ Chemotherapy-Induced Diarrhea Therapeutics Market Analysis
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Chemotherapy-Induced Diarrhea market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Chemotherapy-Induced Diarrhea market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chemotherapy-Induced Diarrhea Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chemotherapy-Induced Diarrhea Epidemiology Segmented by –
- Diagnosed and Treatable Cases of Chemotherapy-Induced Diarrhea in 7MM (2019-32)
- Total Prevalence of Chemotherapy-Induced Diarrhea in the 7MM (2019-32)
- Severity-Specific Prevalence of Chemotherapy-Induced Diarrhea in the 7MM (2019-32)
- Total Prevalence of Chemotherapy-Induced Diarrhea based on Chemotherapeutic regimen in the 7MM (2019-32)
Explore how Chemotherapy-Induced Diarrhea Epidemiology is Evolving in the 7MM @ Chemotherapy-Induced Diarrhea Epidemiology Trends
Chemotherapy-Induced Diarrhea Drugs Uptake and Pipeline Development Activities
The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chemotherapy-Induced Diarrhea market or expected to get launched during the study period. The analysis covers the Chemotherapy-Induced Diarrhea market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chemotherapy-Induced Diarrhea pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Treatment for chemotherapy-related diarrhea (CRD) includes nonpharmacologic and pharmacologic interventions to slow diarrhea and careful serial evaluation to assess response to therapy and to rule out significant volume depletion or other risk factors that would require targeted intervention or hospitalization. Medications such as loperamide and diphenoxylate plus atropine are frequently used along with nonpharmacologic measures to treat mild Chemotherapy-Induced Diarrhea.
Emerging treatments, including those targeting the enteric nervous system, present promising avenues to alleviate Chemotherapy-Induced Diarrhea. Identifying potential targets for novel therapies to alleviate chemotherapy-induced toxicity is essential to improve clinical outcomes and quality of life among cancer sufferers. Currently, only a few companies are actively involved in developing therapies for Chemotherapy-Induced Diarrhea; however, considering the disease burden associated with Chemotherapy-Induced Diarrhea, there is a dire need for novel therapies to cater to the patient’s needs.
Some of the Key Companies in the Chemotherapy-Induced Diarrhea Therapeutics Market Include:
- AzuRx BioPharma
- OnQuality Pharmaceuticals
- Immunic Therapeutics
- Napo Pharmaceuticals [Jaguar Health]
And Many Others
Chemotherapy-Induced Diarrhea Emerging and Marketed Drugs Covered in the Report Include:
- FW-420: AzuRx BioPharma
- OQL051: OnQuality Pharmaceuticals
- IMU-856: Immunic Therapeutics
- MYTESI/crofelemer (Napo Pharmaceuticals [Jaguar Health])
And Many More
In-depth Details of the Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @ Chemotherapy-Induced Diarrhea Therapeutic Market Outlook
Scope of the Chemotherapy-Induced Diarrhea Market Report:
- Study Period – 2019-2032
- Geography Covered – 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
- Key Companies In the Market Include – AzuRx BioPharma, OnQuality Pharmaceuticals, Immunic Therapeutics, Napo Pharmaceuticals [Jaguar Health]
- Marketed and Emerging Drugs – FW-420, OQL051, IMU-856, MYTESI/crofelemer, Loperamide
- Competitive Intelligence Analysis – SWOT Analysis, PESTLE Analysis, Porter’s Five Forces, BCG Matrix, Market Entry Strategies
Visit to Get More Key Insights @ Chemotherapy-Induced Diarrhea Market Trends and Developments
Table of Content
|4||Chemotherapy-Induced Diarrhea Competitive Intelligence Analysis|
|5||Chemotherapy-Induced Diarrhea Market Overview at a Glance|
|6||Chemotherapy-Induced Diarrhea Disease Background and Overview|
|7||Chemotherapy-Induced Diarrhea Patient Journey|
|8||Chemotherapy-Induced Diarrhea Epidemiology and Patient Population (In the US, EU5, and Japan)|
|9||Chemotherapy-Induced Diarrhea Treatment Algorithm, Current Treatment, and Medical Practices|
|10||Chemotherapy-Induced Diarrhea Unmet Needs|
|11||Key Endpoints of Chemotherapy-Induced Diarrhea Treatment|
|12||Chemotherapy-Induced Diarrhea Marketed Products|
|13||Chemotherapy-Induced Diarrhea Emerging Drugs and Latest Therapeutic Advances|
|14||Chemotherapy-Induced Diarrhea Seven Major Market Analysis|
|16||Chemotherapy-Induced Diarrhea Market Outlook (In US, EU5, and Japan)|
|17||Chemotherapy-Induced Diarrhea Access and Reimbursement Overview|
|18||KOL’s Views on the Chemotherapy-Induced Diarrhea Market|
|19||Chemotherapy-Induced Diarrhea Market Drivers|
|20||Chemotherapy-Induced Diarrhea Market Barriers|
Download Sample PDF to Explore More About the Key Offerings of the Report @ Chemotherapy-Induced Diarrhea Therapeutics Market Outlook and Forecast 2032
Chemotherapy-Induced Diarrhea Epidemiology Forecast
“Chemotherapy-induced Diarrhea (CID) Epidemiology Forecast 2032” report delivers an in-depth understanding of the CID, historical and forecasted epidemiology as well as the CID market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
“Chemotherapy-Induced Diarrhea Pipeline Insight, 2023” report outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chemotherapy-Induced Diarrhea market. A detailed picture of the Chemotherapy-Induced Diarrhea pipeline landscape is provided, which includes the disease overview and Chemotherapy-Induced Diarrhea treatment guidelines.
“Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Chemotherapy Induced Anemia in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
“Chemotherapy-induced nausea and vomiting (CINV) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as CINV market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
“Chemotherapy Induced Febrile Neutropenia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the CIFN market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
“Chemotherapy Induced Pain Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chemotherapy Induced Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Leverage the potential of consulting services to overcome the competition in the highly evolving and dynamic healthcare market with DelveInsight’s Healthcare Partner Identification Solutions and Healthcare Portfolio Management Services.
Other Trending Reports:
- Apraxia Market
- Hip Replacement Devices Market
- Global Electrophysiology Devices Market
- Acute Radiation Syndrome Market
- Bronchial Spasm Market
- Interbody Cages Market
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Manager (Marketing & Branding)